BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEBRICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its.
BioAge stock rallies 29% following upsized $198M IPO
WEB1 day ago · BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
WEB20 hours ago · BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on...
BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEB1 day ago · RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
BioAge Labs IPO: stock price today in high-profile Nasdaq debut
WEB1 day ago · California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
BioAge Labs, A New Obesity Treatment Name, Rockets On Upsized IPO …
WEB1 day ago · BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments. The company is working on a drug that mimics apelin, which is...
BioAge brings in $198M from IPO as obesity biotech joins Nasdaq
WEB1 day ago · BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its lead obesity drug further into clinical trials.
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On …
WEBBioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.
BioAge prices $198M IPO, validating pivot to obesity drug research
WEB2 days ago · BioAge Labs has raised $198 million in an initial public offering, the company announced Wednesday, capitalizing on intense investor interest in drugs that can promote weight loss.
Weight loss drug maker BioAge Labs eyes $200 million IPO - Quartz
WEB2 days ago · BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently expanded, planned initial public offering, according to a filing with...
- Some results have been removed